# Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

> **NCT06681220** · PHASE1,PHASE2 · RECRUITING · sponsor: **VA Office of Research and Development** · enrollment: 166 (estimated)

## Conditions studied

- Relapsed Small Cell Lung Cancer
- Recurrent Small Cell Lung Cancer

## Interventions

- **COMBINATION_PRODUCT:** Stenoparib/Temozolomide
- **DRUG:** Lurbinectedin
- **COMBINATION_PRODUCT:** Stenoparib/Temozolomide

## Key facts

- **NCT ID:** NCT06681220
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-23
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 166 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06681220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06681220, "Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06681220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*